

IMI 10th Anniversary Scientific Symposium

Agenda Day 1 22.10.18

22.10.2018 • Crowne Plaza Le Palace •
Rue Gineste 3 • 1210 Brussels • Belgium

08:30 – 09:00 Registration & welcome coffee

09:00 – 10:00 Opening session

Pierre Meulien, Executive Director, IMI
Jean-Christophe Tellier, Chief Executive Officer and Chairman of the Executive Committee, UCB
Jonathan Knowles, Professor, Founding Chairman of IMI Board

10:00 – 11:00 Stratification towards personalised medicines

10:00 – 10:15 Setting the scene

- Pierre Meulien, Executive Director, IMI

10:15 – 11:00 Presentation of key achievements from IMI projects

- *“Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Mechanisms”*
AETIONOMY - Fröhlich Holger, UCB
- *“Quantitative PET Imaging - From Research to Clinical Use”*
AMYPAD - Heeman Fiona, VU University medical centre
- *“Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: A showcase from the epidemiological studies within the IMI DIRECT Consortium”*
DIRECT - Koivula Robert, University of Oxford

11:00 – 11:30 Coffee break

11:30 – 12:15 Presentation of key achievements from IMI projects

- *“Predicting Cognitive Decline through Structural MRI biomarkers: Results from the EMIF-AD Biomarker Discovery Study”*
EPAD - Ingala Silvia, VU Medical Center
- *“The EU-AIMS Longitudinal European Autism Project: Examples of novel approaches to biomarker discovery”*
EU-AIMS - Stefan Holiga, F. Hoffmann-La Roche & Loth Eva, King's College London
- *“Biomarker methods to enable stratification of patient populations in clinical trials for neuropathic pain”*
EUROPAIN - Vollert Jan, Imperial College London



- *“Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors”*
Onco Track - Schütte Moritz, Alacris Theranostics GmbH
- *“Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression”*
PRECISESADS - Toro Daniel, GENYO

12:15 – 13:30 Lunch

- 13:30 – 14:00 Presentation of key achievements from IMI projects
- *“Federating clinical data for biomedical research in type 2 diabetes”*
RHAPSODY - Sparsø Thomas, Novo Nordisk
 - *“Building handprints of complex diseases – severe asthma as a proof of concept”*
U-BIOPRED and eTRIKS - De Meulder Bertrand, European Institute for Systems Biology and Medicine
- 14:00 – 14:30 Panel discussion:
- Pamela Tenaerts, Executive Director, Clinical Trial Transformation Initiative
 - Raj Long, Deputy Director - Integrated Development, Global Health, Bill & Melinda Gates Foundation
 - Martin Hofmann-Apitius, Head of the Department of Bioinformatics, Fraunhofer SCAI
 - Maria Beatriz Da Silva Lima, Professor of Pharmacology and Pharmacotoxicology, Lisbon University

14:30 – 15:00 Coffee break

15:00 – 17:15 Patient centric approaches in drug development

- 15:00 – 15:15 Setting the scene
- Virginie Hivert, Therapeutic Development Director, EURORDIS
- 15:15 – 16:45 Presentation of key achievements from IMI projects
- *“Patient involvement in the IMI-APPROACH project: invaluable insights and key ingredients”*
APPROACH - Hussaarts Leonie, Lygature & Jane Taylor
 - *“Patient education is a prerequisite for meaningful patient engagement in the life cycle of medicines”*
EUPATI - Bereczky Tamàs, Eupati
 - *“Driving the use of Real World Evidence in healthcare decision making”*
GETREAL - Makady Amr, Zorginstituut Nederland
 - *“When to consider patient preference information along the medical product lifecycle? An overview of decision points and situations”*
PREFER - Chiara Whichello and Eline van Overbeek, KU Leuven



- *“From development to labelling claim”*
PRO-active - Demeyer Heleen, Uz Gasthuisberg
- *“Baseline characteristics of participants of the SPRINTT randomised clinical trial”*
SPRINTT - Riccardo Calvani, Università Cattolica del Sacro Cuore

16:45 – 17:15

Panel discussion:

- Virginie Hivert, Therapeutic Development Director, EURORDIS
- Mary Baker, President, European Brain Council
- Fernand Sauer, Member, Académie National de Pharmacie
- Olivier Arnaud, Senior Director, European Research JDRF

17:15 – 19:15

Poster session

18:00 – 22:00

Networking cocktail



Agenda

Day 2

23.10.18

23.10.2018 • Crowne Plaza Le Palace •
Rue Gineste 3 • 1210 Brussels • Belgium

08:30 – 09:00 Registration & welcome coffee

09:00 – 09:15 Introduction

09:00 – 09:15 Pierre Meulien, Executive Director, IMI

09:15 – 11:15 Enablers for discovery and development of new drugs


09:15 – 09:30 Setting the scene

- Jan Egebjerg, Senior Director, Neurodegeneration Discovery Biology, Janssen

09:30 – 11:15 Presentation of key achievements from IMI projects

- *“An iPSC technology development collaboration – a critical component to enable ADAPTED”*
ADAPTED - Peter Reinhardt, AbbVie & Benjamin Schmid, Bioneer
- *“Exploring the potential of lipidoid-polymer hybrid nanoparticles to deliver oligonucleotides to intracellular pharmacological targets”*
COMPACT - Thanki Kaushik, University of Copenhagen
- *“Supporting stem cell research with modern data management technologies”*
EBISC - Seltmann Stefanie, Charité Berlin
- *“EMIF Catalogue – the bridge between data custodians and biomedical researchers”*
EMIF - Trifan Alina, University of Aveiro
- *“HARMONY Platform: using Big Data to fight blood cancers”*
HARMONY - Abáigar-Alvarado Maria, Institute of Biomedical Research of Salamanca
- *“Supersaturation as driving force for intestinal absorption resulting in an increased oral bioavailability: case example with posaconazole”*
ORBITO - Bart Hens, KU Leuven
- *“Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): Study protocol”*
RADAR-CNS - Matcham Faith, King's College London

11:15 – 11:45 Coffee break




- 11:45 – 12:15 Panel discussion:
- Jan Egebjerg, Senior Director, Neurodegeneration Discovery Biology, Janssen
 - Stefan Jaroch, Head External Innovation Technologies, R&D Pharmaceuticals, Bayer AG
 - Magali Haas, CEO & President, Cohen Veterans Bioscience
 - Heiko Zimmermann, Head of Institute, Fraunhofer-Institut für Biomedizinische Technik IBMT
 - Hans-Georg Eichler, Senior medical officer, European Medicines Agency

12:15 – 13:30 Lunch


13:30 – 15:30 Collaborating to fight infections

- 13:30 – 13:45 Setting the scene
- Rino Rappuoli, Chief Scientist & Head of External Research and Development, GlaxoSmithKline
- 13:45 – 15:00 Presentation of key achievements from IMI projects
- *“EURECA - Substudy of infections due to carbapenem-resistant Enterobacteriaceae (CRE) along Europe. Inside COMBACTE network; global information for a global problem”*
COMBACTE-CARE - Paniagua Maria, Hospital Universitario Virgen Macarena
 - *“A new European network for influenza vaccine effectiveness studies”*
DRIVE - Turunen Topi, FISABIO
 - *“Field validation of novel diagnostic tools for Ebola virus detection in Sierra Leone”*
EbolaMoDRAD - Colavita Francesca, INMI
 - *“Modelling the humoral immune response to Ebola vaccine”*
EBOVAC1 - Balelli Irene, Inserm
 - *“Highly potent heavy chain only antibodies protect against MERS-CoV infection”*
ZAPI - Okba Nisreen, Erasmus Medical Center
- 15:00 – 15:30 Panel discussion:
- Rino Rappuoli, Chief Scientist & Head of External Research and Development, GlaxoSmithKline
 - Raj Long, Deputy Director - Integrated Development, Global Health, Bill & Melinda Gates Foundation
 - Seamus O'Brien, R&D Director, Global Antibiotic Research and Development Partnership (GARDP)
 - Isabelle Bekeredjian-Ding, Head of the Department of Microbiology, Paul-Ehrlich-Institut



15:30 – 16:00 Coffee break

16:00 – 17:00 Closing & Prize ceremony




Poster Session


22 & 23.10.2018 • Crowne Plaza Le Palace •
Rue Gineste 3 • 1210 Brussels • Belgium

New targets, tools and pathways


- 1- *“Support Translation Research with High Quality Data and Interactive Visual-analytics”*
eTRIKS - Rege Kavita, University of Luxembourg
- 2- *“Developing a robust evidence base on RSV disease and economic burden using a multi-disciplinary approach”*
RESCEU - Reeves Rachel, the University of Edinburgh
- 3- *“AMYPAD Diagnostic and Patient Management Study (AMYPAD-DPMS): rationale and study design”*
AMYPAD - Altomare Daniele, IRCCS Fatebenefratelli
- 4- *“Network-based modeling of APAP-induced hepatotoxicity using interactomics and transcriptomics data”*
TransQST - GuneyEmre, GRIB - IMIM / UPF
- 5- *“Stroke Risk, Bleeding Risk and Anticoagulation in Hospital EHRs”*
Big data @ heart - Bean Daniel, King's College London & HDR UK
- 6- *“DPP6 as a new biomarker suitable for human islet in vivo imaging”*
INNODIA - Demine Stéphane, ULB Center for Diabetes Research
- 7- *“Identification of Stratified Social-Behavioural Markers in Neuropsychiatric Disorders by using smartphone technology”*
PRISM - Jongs Niels, Rijksuniversiteit Groningen
- 8- *“Drug Evaluation in Guinea Pig Model”*
PreDiCT TB - Lanni Faye, Public Health England
- 9- *“The APPROACH Consortium: a 2-year, European, cohort study to describe, validate, and predict phenotypes of knee osteoarthritis using clinical, imaging, and biochemical markers”*
APPROACH - Van HelvoortEefje, University Medical Centre Utrecht
- 10- *“In vivo models of Drug-induced interstitial lung disease; tools to study and improve drug safety”*
TRISTAN - Mahmutovic Persson Irma, Lund University
- 11- *“RNA-sequencing of medulloblastoma patient-derived orthotopic xenograft models enables identification of both tumor and microenvironment specific biomarkers”*
ITCC-P4 - Jäger Natalie, DKFZ and KiTZ, Heidelberg
- 12- *“Molecular characterization of patient-derived orthotopic xenograft models of paediatric brain tumours”*
ITCC-P4 - Brabetz Sebastian, Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ)



- 13- *“Candidate genes and pathways from ADAPTED Stage I integrative analysis”*
ADAPTED - Madrid Márquez Laura, CAEBi Bioinformatica
- 14- *“Increased understanding of AD pathophysiology through novel cerebrospinal fluid markers: results from the EMIF-AD Multimodal Biomarker Discovery study”*
EMIF-AD - Bos Isabelle, Maastricht University
- 15- *“Data analytics and bioinformatics to successfully define asthma subphenotypes”*
U-BIOPRED - Pavlidis Stelios, Data Science Institute, Imperial College London
- 16- *“Collaborative capacity building: Creating new knowledge, new tools, new collaborative ties and educating young scientist”*
K4DD - Sliedrecht Tale, Lygature
- 17- *“Developing a mechanism-based taxonomy of Alzheimer’s and Parkinson’s disease”*
AETIONOMY - Golriz Khatami Sepehr, Fraunhofer SCAI
- 18- *“Proteome analyses in colorectal carcinoma reveals major protein alterations upon cancer development and metastasis”*
OncoTrack - AzimiAlireza, Uppsala University
- 19- *“Human iPSC-derived cells: a powerful tool for neuropathic pain disease modelling”*
NGN-PET - Rutigliano Lucia, Axxam
- 20- *“A new way to monitor Multiple Sclerosis”*
RADAR-CNS - Martinis Matteo, San Raffaele Hospital
- 21- *“Discovery of the role of the ELOVL2/docosahexaenoic acid axis in the regulation of insulin secretion and survival of rodent and human pancreatic beta cells”*
IMIDIA - Bellini Lara, Université Paris Diderot
- 22- *“Glucagon and gastrointestinal hormones changes after Roux-en-Y gastric bypass: an IMI DIRECT study”*
DIRECT - Frau Francesca, Sanofi
- 23- *“Application and optimization of Monocyte Activation Test for testing Tick Borne Encephalitis virus vaccine pyrogenicity”*
VAC2VAC - Etna Marilena Paola, istituto Superiore di Sanità
- 24- *“Development of Rift Valley fever virus neutralizing antibodies using bacterial superglues”*
ZAPI - Wichgers Schreur Paul, Wageningen Bioveterinary Research
- 25- *“Interim Pharmacokinetic Analysis from the EVADE Phase 2 Clinical Trial of MEDI3902, a Bispecific Monoclonal Antibody Against PcrV and Psl of Pseudomonas aeruginosa”*
COMBACTE-MAGNET - Hernandez Ana Catalina, Centre Hospitalier Universitaire de Limoges
- 26- *“Interim Pharmacokinetic Analysis from the SAATELLITE Phase 2 Clinical Trial of MEDI4893, an Extended Half-life Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin”*
COMBACTE-NET - Hernandez Ana Catalina, Centre Hospitalier Universitaire de Limoges




- 27- *“Urinary metabolites as potential biomarkers of P. aeruginosa ventilator-associated pneumonia”*
RAPP-ID - Jongers Bart, University of Antwerp
- 28- *“Laboratory Analysis workflows within the ASPIRE-ICU study”*
COMBACTE-NET and COMBACTE-MAGNET - Timbermont Leen, University of Antwerp
- 29- *“New bio-informatic approach for the analysis of flow cytometry data”*
PRECISESADS - Le Lann Lucas, University of Brest
- 30- *“Zebrafish Proteinopathy Models for Target Validation”*
IMPRiND - Hubbard Jeffrey, Institut de Recherches Servier
- 31- *“New candidate genes in insulin target tissues: Elovl2 as a protective enzyme against glycaemic deterioration?”*
RHAPSODY - Lallement Justine, Université Paris Diderot
- 32- *“Integration of models of drug-induced liver injury for risk assessment”*
Trans-QST and MIP-DILI - Sison-Young Rowena, University of Liverpool
- 33- *“Isocyanide Chemistry (IMCR): Promising Technology For Future Drug Discovery And Development”*
ELF - Pravin Patil, University Of Groningen
- 34- *“Developing human cellular phenotypic assays for pain”*
StemBANCC - Chintawar Satyan, University of Oxford
- 35- *“Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells”*
OncoTrack - Regan Joseph, Charité - Universitätsmedizin Berlin
- 36- *“A validated genetics-led system ‘Pi’ enables drug target discovery for immune traits”*
ULTRA-DD - Fang Hai, University Of Oxford
- 37- *“Immunobridging approach to assess clinical benefit as the basis for licensure of the monovalent Ebola vaccine”*
EBOVAC 1 and 2 - Bockstal Viki, Janssen Vaccines & Prevention
- 38- *“A Bordetella pertussis human challenge model induces immunising colonization in absence of symptoms”*
PERISCOPE - Hans de Graaf, University of Southampton
- 39- *“Translational Safety Assessment in Pharma”*
eTRANSAFE - Ruud Bueters, Janssen
- 40- *“In vitro antimicrobial activity of tobramycin, colistin, aztreonam and the new antibiotic POL7080 against cystic fibrosis Pseudomonas aeruginosa growing in biofilms”*
iABC - Díez-Aguilar María, Hospital Universitario Ramón y Cajal-IRyCIS
- 41- *“Comparative assessment of seed extraction methods relevant for the study of Alzheimer disease”*
IMPRiND - Delay Charlotte, Janssen Pharmaceuticals



- 42- *"Frequencies of cerebrospinal fluid ATN biomarker profiles and their association with memory function in persons without dementia"*
EMIF-AD - Jansen Olin, Maastricht University

From concept to trial


- 43- *"Developing predictive in silico models for liver toxicity endpoints from in vivo histopathology data"*
eTOX - Pinto Gil Kevin, University Pompeu Fabra
- 44- *"Prognostic factors and outcome of multiple myeloma patients enrolled in European clinical trials after a long-term follow-up. A pilot project by multiple myeloma community within HARMONY consortium"*
HARMONY - D'Agostino Mattia, University of Turin
- 45- *"Altering disease course before symptom onset: the European Prevention of Alzheimer's Dementia (EPAD) project (WP4)"*
EPAD - Gheorghe Delia, University of Oxford
- 46- *"COMBACTE LAB-Net, a European laboratory network for clinical trials on anti-infectives to combat bacterial resistance"*
COMBACTE-NET - Kostyanev Tomislav, University of Antwerp
- 47- *"Tools to collect data on detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories part of the COMBACTE Laboratory network (LAB-Net)"*
COMBACTE-CARE and COMBACTE-NET - Kostyanev Tomislav, University of Antwerp
- 48- *"Exploring MMN processing in Autism Spectrum Disorder during the odd-ball task: evidence from the EU-AIMS LEAP cohort"*
EU-AIMS - Ahmad Jumana, King's College London
- 49- *"Novel peptide vaccines against Rift valley fever virus"*
ZAPI - Gutjahr Benjamin, Friedrich-Loeffler-Institut FLI
- 50- *"Identifying priority outcomes and understanding meaningful delay in disease progression for Alzheimer's Disease across the spectrum"*
ROADMAP - Ly Amanda, University of Edinburgh
- 51- *"Developmental changes in resting state power spectrum and functional connectivity in autism spectrum disorder"*
EU-AIMS - Garces Pilar, Roche
- 52- *"Implementing a Phase II Ebola Vaccine Trial (EBOVAC2) in Burkina Faso"*
EBOVAC2 - Houreratou Barry, Centre MURAZ
- 53- *"A systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals"*
EQIPD - Vollert Jan, Imperial College London
- 54- *"A Highly Productive Semi-Automated High Throughput Purification Process"*
ELF - Levy Laura Mariana, Taros



- 55- *"The Design and Synthesis of Innovative 3D Rich Scaffolds for Screening Libraries"*
ELF - Hristeva Stanimira, Taros
- 56- *"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination: an observational cohort study"*
EBOVAC & EBOPLUS - Santoro Francesco, University of Siena
- 57- *"Transcriptomic analysis of the immune response to the rVSV-ZEBOV Ebola vaccine"*
VSV-EBOVAC - VSV-EBOPLUS - Santoro Francesco, University of Siena

New clinical and regulatory paradigms

- 58- *"What is responsible antibiotic use? Towards a global definition"*
DRIVE-AB - Monnier Annelie, Radboud University Medical Center & Hasselt University
- 59- *"The added value of quantitative amyloid PET in determining Alzheimer's Disease (AD) dementia risk: the AMYPAD Prognostic and Natural History Study"*
AMYPAD - Lopes Alves Isadora, VU Medical Center Amsterdam
- 60- *"Towards an adaptive mindset"*
ADAPT SMART - Rohou Solange, Astrazeneca
- 61- *"Regulatory and HTA considerations for disease-modifying drugs in Alzheimer's disease"*
ROADMAP - O'RourkeDiana, National Institute for Health and Care Excellence (NICE)
- 62- *"Time-to-event case-control designs: An efficacious tool for cohort studies on nosocomial infections when resources are limited"*
COMBACTE - Feifel Jan, Ulm University
- 63- *"European Prevention of Alzheimer's Dementia (EPAD) Registry for a longitudinal cohort and Alzheimer prevention trials"*
EPAD - Vermunt Lisa, VU University Medical Center
- 64- *"Prioritisation and Intelligent Assessment of the Environmental Risks of Pharmaceuticals"*
iPiE - Wilkinson John, University of York
- 65- *"Alignment of European regulatory and health technology assessments: a review of licensed products for Alzheimer's Disease"*
ROADMAP - DekkerMarieke, Medicines Evaluation Board (MEB-CBG)
- 66- *"IMI-PROTECT and benefit risk assessment"*
PROTECT - Waddingham Edward, Imperial College London
- 67- *"Managing false-positive Ebola test results in the post-outbreak era: Experiences in the EBOVAC vaccine trial in rural Sierra Leone"*
EBOVAC - Baiden Frank, London School of Hygiene and Tropical Medicine



Patient engagement along the value chain

68- *“Characterising and appraising patient preference exploration and elicitation methods”*
PREFER - Whichello Chiara, Erasmus University Rotterdam

69- *“Prospective data collection on burden of RSV infection in Europe – paving the way for RSV vaccines and therapeutics”*
RESCEU - Wildenbeest Joanne G, Wilhelmina Children's Hospital, University Medical Center Utrecht

70- *“Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes”*
PARADIGM - Pakarinen Chi, the Synergist

71- *“Lessons learned in the recruitment of adolescents and children to the EBOVAC-Salone clinical trial in Sierra Leone”*
EBOVAC1 - Shona Lee, EBOVAC Salone, Social Science Team

72- *“Bridging the gap between intention and action - Lessons learned from INNODIA's Patient Advisory Committee”*
INNODIA - Soderberg Jeannette, JDRF

